Research & Clinical Trials

As the only national nonprofit advocacy organization focused on hereditary breast and ovarian cancer, FORCE has a strong commitment to promoting research.

| More


Study of BMN 673, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors

Study identifier: NCT01286987
Full study details on

Name of PARP Inhibitor used in study:

BMN 673 (BioMarin)


  • Breast cancer patients with deleterious or pathogenic BRCA mutations who have received no more than 4 prior regimens for metastatic disease.

Type of study:

Phase I


  • Patients receive BMN 673 orally once daily.

Study sites:

TGen Clinical Research Services
Scottsdale, Arizona, 95258
Contact: Joyce Schaffer, MSN RN OCN 480-323-1339
Principal Investigator: Ramesh Ramanathan, MD

University of California Los Angeles (UCLA)
Santa Monica, California, United States, 90404
Contact: Lisa M Yonemoto 310-582-4069
Principal Investigator: Zev Wainberg, MD

Indiana University Simon Cancer Center Recruiting
Indianapolis, Indiana, United States, 46202
Principal Investigator: Lida Mina, MD
Contact: Ashley Grist 317-278-6680

University of Michigan Health System Recruiting
Ann Arbor, Michigan, United States, 48109
Contact: Nabeela Iqbal 734-232-0759
Principal Investigator: Rashmi Chugh, MD

University of Texas MD Anderson Cancer Center Recruiting
Houston, Texas, United States, 77030
Principal Investigator: Lauren A Byers, MD
Contact: Beena Varghese-Cortes, RN 713-792-3850
Contact: Griselda Parra

United Kingdom
Royal Marsden Hospital
Sutton, United Kingdom, SM2 5PT
Contact: Sonia Serrano +44 (0) 20 8722 4087
Principal Investigator: Johann de Bono, MD

Page updated 04/06/14

FORCE:Facing Our Risk of Cancer Empowered